Breaking News Instant updates and real-time market news.

PCTY

Paylocity

$114.32 /

+1.395 (+1.24%)

, MDP

Meredith

$14.84 /

-0.34 (-2.24%)

04:55
05/01/20
05/01
04:55
05/01/20
04:55

Paylocity to replace Meredith in S&P 400 at open on 5/1

PCTY

Paylocity

$114.32 /

+1.395 (+1.24%)

MDP

Meredith

$14.84 /

-0.34 (-2.24%)

  • 07

    May

PCTY Paylocity
$114.32 /

+1.395 (+1.24%)

04/16/20
Fly Intel: Top five analyst downgrades
04/16/20 Stifel
Paylocity downgraded to Hold from Buy at Stifel
04/15/20 Stifel
Paylocity downgraded to Hold from Buy at Stifel
03/27/20 Truist
Paylocity price target lowered to $115 from $162 at SunTrust
MDP Meredith
$14.84 /

-0.34 (-2.24%)

03/06/20 Benchmark
Meredith dividend looks 'very safe,' says Benchmark
01/07/20 Citi
Citi makes changes to 'Value Creators' SMID Focus List
12/11/19 Guggenheim
Guggenheim says Nexstar, Gray best positioned for 'record' political cycle
11/19/19 Stephens
Meredith price target lowered to $40 from $65 at Stephens

TODAY'S FREE FLY STORIES

General news
FX Update: The dollar has corrected some of Friday's gains » 03:45
03/01/21
03/01
03:45
03/01/21
03:45

FX Update: The dollar has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
Asian Market Update: » 03:05
03/01/21
03/01
03:05
03/01/21
03:05

Asian Market Update: Bond…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
U.S. Markit manufacturing PMI » 03:05
03/01/21
03/01
03:05
03/01/21
03:05

U.S. Markit manufacturing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
U.S. construction spending preview » 03:05
03/01/21
03/01
03:05
03/01/21
03:05

U.S. construction…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
U.S. ISM manufacturing index preview » 03:05
03/01/21
03/01
03:05
03/01/21
03:05

U.S. ISM manufacturing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
Vector Acquisition near deal to take Rocket Lab USA public, WSJ reports » 20:46
02/28/21
02/28
20:46
02/28/21
20:46
VACQ

Vector Acquisition

$10.27 /

-0.01 (-0.10%)

Space-transportation…

Space-transportation startup Rocket Lab USA is nearing an agreement to go public by merging with Vector Acquisition (VACQ), Cara Lombardo of Wall Street Journal reports, citing people familiar with the matter. The deal values Rocket Lab at around $4.1B including debt and could be finalized by Monday, sources told the Journal. It is expected to include additional funds of about $470M in the form of a private investment in public equity from investors including BlackRock (BLK) and Neuberger Berman Group, the sources added. Reference Link

ShowHide Related Items >><<
VACQ Vector Acquisition
$10.27 /

-0.01 (-0.10%)

Upgrade
Wolters Kluwer upgraded to Neutral from Sell at Goldman Sachs » 20:43
02/28/21
02/28
20:43
02/28/21
20:43
WTKWY

Wolters Kluwer

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Katherine Tait upgraded Wolters Kluwer to Neutral from Sell with a price target of EUR 72.60, up from EUR 68.80. The analyst cites valuation following the stock's recent underperformance and the company's improving margin outlook in 2021 for the upgrade.

ShowHide Related Items >><<
WTKWY Wolters Kluwer
$0.00 /

+ (+0.00%)

WTKWY Wolters Kluwer
$0.00 /

+ (+0.00%)

02/25/21 Barclays
Wolters Kluwer price target lowered to EUR 69 from EUR 71.50 at Barclays
02/25/21 Credit Suisse
Wolters Kluwer price target lowered to EUR 78.60 from EUR 80 at Credit Suisse
01/29/21 Barclays
Wolters Kluwer price target lowered to EUR 71.50 from EUR 72 at Barclays
01/12/21 Berenberg
Wolters Kluwer price target raised to EUR 70 from EUR 69 at Berenberg
Recommendations
Albireo Pharma price target raised to $81 from $68 at Piper Sandler » 20:41
02/28/21
02/28
20:41
02/28/21
20:41
ALBO

Albireo Pharma

$34.82 /

-0.29 (-0.83%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi raised the firm's price target on Albireo Pharma to $81 from $68 and keeps an Overweight rating on the shares. Following the earnings update, the analyst remains confident that Albireo is on track to launch odevixibat in the second half of 2021, with an FDA action date set for July 20. Her target raise is driven by odevixibat's "billion-dollar market opportunity" in biliary atresia.

ShowHide Related Items >><<
ALBO Albireo Pharma
$34.82 /

-0.29 (-0.83%)

ALBO Albireo Pharma
$34.82 /

-0.29 (-0.83%)

01/25/21 Piper Sandler
NDA acceptance 'a big win' for Albireo Pharma, says Piper Sandler
09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
ALBO Albireo Pharma
$34.82 /

-0.29 (-0.83%)

  • 10
    Sep
ALBO Albireo Pharma
$34.82 /

-0.29 (-0.83%)

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:03
02/28/21
02/28
20:03
02/28/21
20:03
JNJ

Johnson & Johnson

$158.52 /

-4.28 (-2.63%)

, BRK.B

Berkshire Hathaway

$240.27 /

-3.35 (-1.38%)

, BRK.A

Berkshire Hathaway

$364,420.00 /

-4355 (-1.18%)

, ROST

Ross Stores

$116.65 /

-2.08 (-1.75%)

, TWLO

Twilio

$392.84 /

+15.295 (+4.05%)

, CG

Carlyle Group

$34.24 /

-0.22 (-0.64%)

, AEP

American Electric

$74.88 /

-1.43 (-1.87%)

, D

Dominion

$68.29 /

-2.31 (-3.27%)

, ETR

Entergy

$86.82 /

-1.26 (-1.43%)

, EXC

Exelon

$38.60 /

-0.32 (-0.82%)

, NEE

NextEra Energy

$73.51 /

-0.55 (-0.74%)

, C

Citi

$65.86 /

-1.54 (-2.28%)

, DOW

Dow Inc.

$59.32 /

-2.055 (-3.35%)

, ASOMY

Asos

$0.00 /

+ (+0.00%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Food and Drug Administration issued an emergency use authorization for the third vaccine for the prevention of coronavirus disease. The EUA allows Johnson & Johnson's (JNJ) Janssen COVID-19 vaccine to be distributed in the U.S for use in individuals 18 years of age and older. Meanwhile, Johnson & Johnson also announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has recommended its single-shot COVID-19 vaccine. The ACIP recommendation will be forwarded to the Director of the CDC and the U.S. Department of Health and Human Services for review and adoption. Johnson & Johnson has begun shipping its COVID-19 vaccine and expects to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20M people in the U.S. The company plans to deliver 100M single-shot vaccines to the U.S. during the first half of 2021. The U.S. government will manage allocation and distribution of the vaccine in the U.S. 2. Warren Buffett Berkshire Hathaway's (BRK.A, BRK.B) fourth quarter profits rose, with its net earnings rising to $38.5B, or $23,015 a Class A share equivalent, up almost 23% from the previous year's profit of $29.2B, or $17,909 a share. Operating earnings, which exclude some investment results, rose to $5 billion from $4.4 billion the year before. Buffett also said in his annual shareholder letter to "never bet against America." "In its brief 232 years of existence... there has been no incubator for unleashing human potential like America," he added. "Despite some severe interruptions, our country's economic progress has been breathtaking. Our unwavering conclusion: Never bet against America." Buffett said the conglomerate owns the biggest amount of U.S. assets by value than any other company in the country. Berkshire Hathaway also bought back a record amount of company stock last year. During the fourth quarter, the company bought back about $9B shares for a total 2020 repurchase of $24.7B. Buffett said in his annual shareholder letter that repurchases have continued since year-end and "is likely to further reduce its share count in the future." 3. Ross Stores (ROST) offers shoppers a chance to find overlooked "treasures" among a heap of discards and its stock could offer investors the same opportunity, Teresa Rivas wrote in this week's edition of Barron's. The company has had a tough time during the pandemic and its stock has took a bigger beating, the author noted. But the underperformance means that Ross also has the most to gain as more vaccines are given and reopening accelerates, Rivas added. 4. Twilio (TWLO) is in talks to invest as much as $750M in Carlyle Group's (CG) Syniverse Technologies in a precursor to a public listing, Cara Lombardo and Dana Cimilluca of Wall Street Journal reported, citing people familiar with the matter. The investment will be announced Monday and could be followed in the coming months by a merger between Syniverse and a special-purpose acquisition company, sources told the Journal. Such a deal could value Syniverse around $2B to $3B including debt, they added. The Twilio deal involves a commercial arrangement that would send a significant amount of business to Syniverse, which provides roaming, messaging and other telecommunications services, the sources said. 5. American Electric Power (AEP), Dominion Energy (D), Entergy (ETR), Exelon (EXC), NextEra Energy (NEE), Citigroup (C), Dow (DOW) and Asos (ASOMY) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

ETR Entergy
$86.82 /

-1.26 (-1.43%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

D Dominion
$68.29 /

-2.31 (-3.27%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

C Citi
$65.86 /

-1.54 (-2.28%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

AEP American Electric
$74.88 /

-1.43 (-1.87%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

01/21/21 Deutsche Bank
Ross Stores price target raised to $129 from $123 at Deutsche Bank
01/04/21 JPMorgan
Ross Stores price target raised to $128 from $125 at JPMorgan
11/20/20 MKM Partners
Ross Stores price target raised to $124 from $105 at MKM Partners
11/20/20 Loop Capital
Ross Stores price target raised to $130 from $110 at Loop Capital
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

02/18/21 Northland
Twilio price target raised to $500 from $390 at Northland
02/18/21 Needham
Twilio price target raised to $500 from $340 at Needham
02/18/21 KeyBanc
Twilio price target raised to $550 from $420 at KeyBanc
02/18/21 Wells Fargo
Twilio price target raised to $525 from $450 at Wells Fargo
CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

02/24/21 Deutsche Bank
Carlyle Group price target raised to $39 from $37 at Deutsche Bank
02/24/21 Barclays
Carlyle Group price target raised to $39 from $36 at Barclays
02/19/21
Fly Intel: Top five analyst upgrades
02/19/21 Credit Suisse
Carlyle Group upgraded to Outperform from Neutral at Credit Suisse
AEP American Electric
$74.88 /

-1.43 (-1.87%)

01/20/21 Guggenheim
American Electric upgraded to Buy from Neutral at Guggenheim
01/14/21 Goldman Sachs
American Electric downgraded to Sell from Neutral at Goldman Sachs
01/12/21
Fly Intel: Top five analyst downgrades
01/12/21 KeyBanc
American Electric downgraded to Sector Weight at KeyBanc
D Dominion
$68.29 /

-2.31 (-3.27%)

01/29/21 Mizuho
Dominion price target raised to $76 from $75 at Mizuho
01/26/21
Fly Intel: Top five analyst upgrades
01/26/21 Wells Fargo
Dominion upgraded to Overweight from Equal Weight at Wells Fargo
01/21/21 Evercore ISI
Dominion upgraded to Outperform from In Line at Evercore ISI
ETR Entergy
$86.82 /

-1.26 (-1.43%)

01/27/21 Mizuho
Entergy price target lowered to $105 from $110 at Mizuho
01/21/21 Evercore ISI
Entergy upgraded to Outperform from In Line at Evercore ISI
11/17/20 Mizuho
Entergy price target raised to $119 from $109 at Mizuho
11/16/20 Wolfe Research
Entergy upgraded to Outperform from Peer Perform at Wolfe Research
EXC Exelon
$38.60 /

-0.32 (-0.82%)

01/06/21 BofA
Exelon upgraded to Buy from Neutral at BofA
12/15/20 BofA
Exelon upgraded to Neutral from Underperform at BofA
12/11/20 Argus
Exelon price target raised to $45 from $42 at Argus
10/26/20
Fly Intel: Top five analyst downgrades
NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

01/27/21 Credit Suisse
NextEra Energy price target raised to $87 from $77 at Credit Suisse
01/27/21 Wells Fargo
NextEra Energy price target raised to $100 from $85 at Wells Fargo
01/20/21 Credit Suisse
NextEra Energy Partners price target raised to $86 from $71 at Credit Suisse
01/11/21 Mizuho
NextEra Energy price target raised to $90 from $64 at Mizuho
C Citi
$65.86 /

-1.54 (-2.28%)

01/21/21 Berenberg
Berenberg downgrades Citi to Hold after 50% rally
01/21/21 Berenberg
Citi downgraded to Hold from Buy at Berenberg
01/19/21 DA Davidson
Citi price target raised to $84 from $77 at DA Davidson
01/19/21 RBC Capital
Citi price target raised to $73 from $66 at RBC Capital
DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

02/22/21 BofA
Dow Inc. upgraded to Neutral from Underperform at BofA
02/22/21 BofA
Dow Inc. upgraded to Neutral from Underperform at BofA
02/09/21 Jefferies
Dow Inc. price target raised to $70 from $68 at Jefferies
01/22/21 JPMorgan
Dow Inc. price target raised to $64 from $60 at JPMorgan
ASOMY Asos
$0.00 /

+ (+0.00%)

02/23/21 Grupo Santander
Asos downgraded to Underweight from Hold at Grupo Santander
02/22/21 Barclays
Asos price target raised to 5,750 GBp from 5,150 GBp at Barclays
02/22/21 RBC Capital
Asos price target raised to 7,500 GBp from 6,000 GBp at RBC Capital
02/11/21 Credit Suisse
Asos price target raised to 7,250 GBp from 6,650 GBp at Credit Suisse
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

ETR Entergy
$86.82 /

-1.26 (-1.43%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

D Dominion
$68.29 /

-2.31 (-3.27%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

C Citi
$65.86 /

-1.54 (-2.28%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

AEP American Electric
$74.88 /

-1.43 (-1.87%)

  • 19
    Feb
  • 07
    Aug
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

D Dominion
$68.29 /

-2.31 (-3.27%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

C Citi
$65.86 /

-1.54 (-2.28%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

ASOMY Asos
$0.00 /

+ (+0.00%)

AEP American Electric
$74.88 /

-1.43 (-1.87%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

C Citi
$65.86 /

-1.54 (-2.28%)

BRK.B Berkshire Hathaway
$240.27 /

-3.35 (-1.38%)

BRK.A Berkshire Hathaway
$364,420.00 /

-4355 (-1.18%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

ROST Ross Stores
$116.65 /

-2.08 (-1.75%)

NEE NextEra Energy
$73.51 /

-0.55 (-0.74%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

EXC Exelon
$38.60 /

-0.32 (-0.82%)

DOW Dow Inc.
$59.32 /

-2.055 (-3.35%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

C Citi
$65.86 /

-1.54 (-2.28%)

Periodicals
AstraZeneca sells stake in Moderna for over $1B, The Times reports » 19:59
02/28/21
02/28
19:59
02/28/21
19:59
AZN

AstraZeneca

$48.37 /

-0.53 (-1.08%)

, MRNA

Moderna

$154.90 /

+6.66 (+4.49%)

AstraZeneca (AZN) has…

AstraZeneca (AZN) has sold its stake in Moderna (MRNA) for more than $1B after the latter's shares soared on the back of its coronavirus vaccine breakthrough, The Times' Alex Ralph reports. AstraZeneca has disposed of its 7.7% holding, which had made it Moderna's second largest investor last year, the author notes. Reference Link

ShowHide Related Items >><<
MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

02/25/21
Fly Intel: Top five analyst upgrades
02/25/21 UBS
AstraZeneca upgraded to Buy from Neutral at UBS
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MRNA Moderna
$154.90 /

+6.66 (+4.49%)

02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
02/25/21 Piper Sandler
Moderna transitioning into profitable company, says Piper Sandler
02/18/21 Jefferies
Moderna price target raised to $180 from $150 at Jefferies
MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

  • 19
    May
MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

MRNA Moderna
$154.90 /

+6.66 (+4.49%)

AZN AstraZeneca
$48.37 /

-0.53 (-1.08%)

Earnings
Liberty Latin America reports Q4 revenue $1.10B, consensus $1.03B » 19:55
02/28/21
02/28
19:55
02/28/21
19:55
LILA

Liberty Latin America

$11.00 /

+0.19 (+1.76%)

, LILAK

Liberty Latin America

$10.97 /

+0.24 (+2.24%)

Reports Q4 adjusted FCF…

Reports Q4 adjusted FCF $89M vs $103M last year. Reports FY20 revenue $3.77B, consensus $3.7B. Reports FY20 adjusted FCF $148M vs $223M in FY19.

ShowHide Related Items >><<
LILAK Liberty Latin America
$10.97 /

+0.24 (+2.24%)

LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

11/05/20 Scotiabank
Liberty Latin America downgraded to Underperform at Scotiabank
11/05/20 Scotiabank
Liberty Latin America downgraded to Underperform from Sector Perform at Scotiabank
10/09/20 Morgan Stanley
Liberty Latin America upgraded to Overweight at Morgan Stanley
03/12/20 HSBC
Liberty Latin America upgraded to Buy from Hold at HSBC
LILAK Liberty Latin America
$10.97 /

+0.24 (+2.24%)

12/04/20 Pivotal Research
Liberty Latin America price target raised to $16 from $13.50 at Pivotal
10/08/20 Goldman Sachs
Liberty Latin America upgraded to Buy from Neutral at Goldman Sachs
09/28/20 Scotiabank
Liberty Latin America upgraded to Sector Perform at Scotiabank
LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

LILA Liberty Latin America
$11.00 /

+0.19 (+1.76%)

Initiation
On24 initiated with a Buy at Goldman Sachs » 19:28
02/28/21
02/28
19:28
02/28/21
19:28
ONTF

On24

$56.34 /

+0.85 (+1.53%)

Goldman Sachs analyst…

Goldman Sachs analyst Christopher Merwin initiated coverage of On24 with a Buy rating and $88 price target. ON24 was a "significant beneficiary" as events shifted completely online in the past year as the company is able to capture rich data from webinar attendees that can be used to add context around a prospective customer's interest and intent to buy, Merwin tells investors in a research note. And if in-person events start to return in late 2021, On24 won't see major growth headwinds as most companies are likely to employ a hybrid strategy going forward and a majority of On24's deals are based on seat count, not webinar usage, says the analyst. Merwin models revenue growth of 30% and 22% in 2021 and 2022, respectively.

ShowHide Related Items >><<
  • 03
    Feb
ONTF On24
$56.34 /

+0.85 (+1.53%)

Periodicals
Herbalife to name three new directors as Icahn ends investment, WSJ reports » 19:24
02/28/21
02/28
19:24
02/28/21
19:24
HLF

Herbalife Nutrition

$44.98 /

+0.18 (+0.40%)

Herbalife Nutrition plans…

Herbalife Nutrition plans to overhaul its board as Carl Icahn winds down his eight-year involvement with the company, Cara Lombardo of Wall Street Journal reports. Herbalife it set to announce Monday three additions to its board: Sophie L'Helias, Kevin Jones and Don Mulligan, according to Lombardo. Following the additions, the board is expected to have nine members after the company's annual meeting this spring as two current directors, Margarita Palau-Hernandez and Michael Montelongo, don't plan to stand for re-election, she adds. Reference Link

ShowHide Related Items >><<
HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

12/24/20 Citi
Herbalife Nutrition price target raised to $66 from $63 at Citi
09/11/20 Jefferies
Herbalife, Nu Skin valuation gaps can close as models transform, says Jefferies
06/22/20 Citi
Citi boosts Herbalife target to $63, opens '90 Day Catalyst Watch'
05/08/20 Jefferies
Herbalife Nutrition price target raised to $45 from $40 at Jefferies
HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

HLF Herbalife Nutrition
$44.98 /

+0.18 (+0.40%)

Periodicals
Twilio nears up to $750M investment in Syniverse, WSJ reports » 19:20
02/28/21
02/28
19:20
02/28/21
19:20
TWLO

Twilio

$392.84 /

+15.295 (+4.05%)

, CG

Carlyle Group

$34.24 /

-0.22 (-0.64%)

Twilio (TWLO) is in talks…

Twilio (TWLO) is in talks to invest as much as $750M in Carlyle Group's (CG) Syniverse Technologies in a precursor to a public listing, Cara Lombardo and Dana Cimilluca of Wall Street Journal report, citing people familiar with the matter. The investment will be announced Monday and could be followed in the coming months by a merger between Syniverse and a special-purpose acquisition company, sources told the Journal. Such a deal could value Syniverse around $2B to $3B including debt, they added. The Twilio deal involves a commercial arrangement that would send a significant amount of business to Syniverse, which provides roaming, messaging and other telecommunications services, the sources said. Reference Link

ShowHide Related Items >><<
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

02/18/21 Northland
Twilio price target raised to $500 from $390 at Northland
02/18/21 Needham
Twilio price target raised to $500 from $340 at Needham
02/18/21 KeyBanc
Twilio price target raised to $550 from $420 at KeyBanc
02/18/21 Wells Fargo
Twilio price target raised to $525 from $450 at Wells Fargo
CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

02/24/21 Deutsche Bank
Carlyle Group price target raised to $39 from $37 at Deutsche Bank
02/24/21 Barclays
Carlyle Group price target raised to $39 from $36 at Barclays
02/19/21
Fly Intel: Top five analyst upgrades
02/19/21 Credit Suisse
Carlyle Group upgraded to Outperform from Neutral at Credit Suisse
TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

  • 19
    Feb
  • 07
    Aug
CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

TWLO Twilio
$392.84 /

+15.295 (+4.05%)

CG Carlyle Group
$34.24 /

-0.22 (-0.64%)

Periodicals
CAE near deal to acquire L3Harris military-training unit, WSJ reports » 19:16
02/28/21
02/28
19:16
02/28/21
19:16
CAE

CAE

$26.47 /

-0.57 (-2.11%)

, LHX

L3Harris Technologies

$181.98 /

-4.99 (-2.67%)

CAE (CAE) is nearing a…

CAE (CAE) is nearing a deal to acquire L3Harris Technologies' military-training division for $1.05B that will be funded by a private placement of roughly C$700M from two institutional investors, Cara Lombardo of Wall Street Journal reports, citing people familiar with the matter. An agreement is expected to be announced Monday for the business which has about $500M in annual revenue, sources tell the Journal. CAE expects the deal to be accretive to earnings and forecasts cost savings of roughly C$35M to C$45M a year in the second year post-close, they added. Reference Link

ShowHide Related Items >><<
LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

CAE CAE
$26.47 /

-0.57 (-2.11%)

CAE CAE
$26.47 /

-0.57 (-2.11%)

02/16/21 TD Securities
CAE price target raised to C$34 from C$33 at TD Securities
02/16/21 Scotiabank
CAE price target raised to C$39 from C$38 at Scotiabank
02/16/21 Canaccord
CAE price target raised to C$34 from C$32 at Canaccord
01/04/21 CIBC
CAE price target raised to C$36 from C$33 at CIBC
LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

02/01/21 Credit Suisse
L3Harris Technologies price target lowered to $200 from $210 at Credit Suisse
02/01/21 Citi
L3Harris Technologies price target lowered to $225 from $235 at Citi
01/07/21 Baird
L3Harris Technologies downgraded to Neutral from Outperform at Baird
12/15/20
Fly Intel: Top five analyst downgrades
LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

CAE CAE
$26.47 /

-0.57 (-2.11%)

LHX L3Harris Technologies
$181.98 /

-4.99 (-2.67%)

CAE CAE
$26.47 /

-0.57 (-2.11%)

Periodicals
Macy's, Gap letting customers buy now, pay later, WSJ reports » 18:12
02/28/21
02/28
18:12
02/28/21
18:12
M

Macy's

$15.20 /

-0.505 (-3.22%)

, GPS

Gap

$24.96 /

-0.27 (-1.07%)

, AFRM

Affirm

$93.06 /

-1.135 (-1.20%)

Chains from Macy's…

Chains from Macy's (M) to Gap (GPS) to Neiman Marcus Group have introduced buy now, pay later options in recent months to attract younger shoppers, who are less likely to use credit cards, The Wall Street Journal's Suzanne Kapner reports. The emerging payment option is a modern take on old-fashioned layaway plans, allowing shoppers to pay for purchases over time, the author notes. Instead of earning a profit from customers who revolve a balance on their store cards, retailers pay fees to the financial-technology companies that offer buy now, pay later plans, including Klarna Bank AB, Affirm Holdings (AFRM) and Afterpay, the publication adds. Reference Link

ShowHide Related Items >><<
M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

M Macy's
$15.20 /

-0.505 (-3.22%)

02/24/21 Credit Suisse
Macy's price target raised to $13 from $7 at Credit Suisse
02/24/21 Deutsche Bank
Macy's price target raised to $16 from $15 at Deutsche Bank
02/18/21 Morgan Stanley
Macy's price target raised to $11 from $6 at Morgan Stanley
01/21/21 Deutsche Bank
Macy's price target raised to $15 from $9 at Deutsche Bank
GPS Gap
$24.96 /

-0.27 (-1.07%)

02/16/21 Jefferies
Gap assumed with a Hold at Jefferies
01/21/21 Deutsche Bank
Gap price target raised to $26 from $25 at Deutsche Bank
01/15/21 B. Riley Securities
Gap price target lowered to $22 from $31 at B. Riley Securities
11/25/20
Fly Intel: Top five analyst downgrades
AFRM Affirm
$93.06 /

-1.135 (-1.20%)

02/16/21 Barclays
Affirm price target raised to $148 from $132 at Barclays
02/12/21 RBC Capital
Affirm price target raised to $155 from $130 at RBC Capital
02/12/21 Morgan Stanley
Affirm price target raised to $146 from $142 at Morgan Stanley
02/08/21
Fly Intel: Top five analyst initiations
M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

  • 13
    Jan
M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

M Macy's
$15.20 /

-0.505 (-3.22%)

GPS Gap
$24.96 /

-0.27 (-1.07%)

AFRM Affirm
$93.06 /

-1.135 (-1.20%)

Periodicals
House approves Biden's $1.9T COVID aid, Reuters reports » 18:08
02/28/21
02/28
18:08
02/28/21
18:08
SPY

SPDR S&P 500 ETF Trust

$380.35 /

-2.04 (-0.53%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

President Joe…

President Joe Biden's $1.9T plan to address the human and economic toll of the COVID-19 pandemic passed the U.S. House of Representatives early on Saturday, with the next step Senate consideration, according to Reuters. Reference Link

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
SPX S&P 500
$0.00 /

+ (+0.00%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$380.35 /

-2.04 (-0.53%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Periodicals
Reliance partners with Google, Facebook for payment network bid, Reuters says » 18:07
02/28/21
02/28
18:07
02/28/21
18:07
FB

Facebook

$257.21 /

+2.63 (+1.03%)

, GOOG

Alphabet

$2,035.58 /

+0.69 (+0.03%)

, GOOGL

Alphabet Class A

$2,020.96 /

+0.6 (+0.03%)

India's conglomerate…

India's conglomerate Reliance Industries has partnered with Facebook (FB), Google (GOOGL) and fintech player Infibeam to set up a national digital payment network, according to Reuters, citing a report by the Economic Times. Last year, India's central bank invited companies to forge new umbrella entities to create a payments network that would rival the system operated by the National Payments Council of India, as it seeks to reduce concentration risks in the space, the report notes. Reference Link

ShowHide Related Items >><<
GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

02/26/21 Jefferies
Twitter price target raised to $79 from $64 at Jefferies
02/16/21 Loop Capital
Facebook price target raised to $370 from $330 at Loop Capital
02/10/21 Tigress Financial
Facebook has 'significant upside' at current levels, says Tigress
02/01/21 Truist
Alphabet price target raised to $2,100 from $2,000 at Truist
GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

02/17/21 Morgan Stanley
Roku price target raised to $275 from $200 at Morgan Stanley
02/12/21 Citi
Citi boosts Alphabet target but shares no longer a top pick
02/08/21 Stephens
Global Payments merchant business advanced by Google pact, says Stephens
02/03/21 JMP Securities
Alphabet price target raised to $2,400 from $1,700 at JMP Securities
GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

02/17/21 Maxim
Kaleyra price target raised to $30 from $22 at Maxim
02/16/21 Loop Capital
Alphabet upgraded to Buy from Hold at Loop Capital
GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

GOOGL Alphabet Class A
$2,020.96 /

+0.6 (+0.03%)

GOOG Alphabet
$2,035.58 /

+0.69 (+0.03%)

FB Facebook
$257.21 /

+2.63 (+1.03%)

Periodicals
Danone takes step to sell Chinese step amid shareholder pressure, Reuters says » 17:59
02/28/21
02/28
17:59
02/28/21
17:59
DANOY

Danone

$0.00 /

+ (+0.00%)

Danone said on Sunday it…

Danone said on Sunday it was taking a first step toward selling off its stake in its Chinese dairy partner as the French food group faces pressure from shareholders to improve its performance and governance, according to Reuters. Danone said that following a review of its portfolio it had reached an agreement to convert its indirect stake in China Mengniu Dairy Company into a 9.8% direct holding in the Hong Kong-listed group, the publication adds. Reference Link

ShowHide Related Items >><<
DANOY Danone
$0.00 /

+ (+0.00%)

DANOY Danone
$0.00 /

+ (+0.00%)

02/26/21 Morgan Stanley
Danone assumed with an Equal Weight at Morgan Stanley
02/23/21 Berenberg
Danone price target raised to EUR 60 from EUR 58 at Berenberg
01/26/21 Societe Generale
Danone price target lowered to EUR 47 from EUR 49 at Societe Generale
01/14/21 Deutsche Bank
Danone price target lowered to EUR 62 from EUR 64 at Deutsche Bank
DANOY Danone
$0.00 /

+ (+0.00%)

DANOY Danone
$0.00 /

+ (+0.00%)

Periodicals
Hyatt calls hate symbols 'abhorrent' after CPAC controversy, Reuters says » 17:56
02/28/21
02/28
17:56
02/28/21
17:56
H

Hyatt

$87.93 /

+0.79 (+0.91%)

Hyatt Hotels called…

Hyatt Hotels called symbols of hate "abhorrent" on Sunday after the design of a stage at the Conservative Political Action Conference at one of its hotels drew comparisons to a Norse rune used by Nazis during World War Two, according to Reuters. High-profile Republicans including former President Donald Trump are attending the four-day event in Orlando, Florida, the publication notes. A photo of the CPAC stage went viral on social media on Saturday, with thousands of Twitter users sharing posts comparing its distinctive design to an othala rune, one of many ancient European symbols that Nazis adopted to "reconstruct a mythic 'Aryan' past," according to the Anti-Defamation League. Reference Link

ShowHide Related Items >><<
H Hyatt
$87.93 /

+0.79 (+0.91%)

H Hyatt
$87.93 /

+0.79 (+0.91%)

02/22/21 Evercore ISI
Hyatt price target raised to $90 from $80 at Evercore ISI
02/19/21 Macquarie
Hyatt price target raised to $67 from $46 at Macquarie
02/19/21 Deutsche Bank
Hyatt price target raised to $69 from $49 at Deutsche Bank
02/12/21 Berenberg
Hyatt downgraded to Sell from Hold at Berenberg
H Hyatt
$87.93 /

+0.79 (+0.91%)

H Hyatt
$87.93 /

+0.79 (+0.91%)

Periodicals
McDonald's considering selling part of Dynamic Yield, Bloomberg reports » 17:47
02/28/21
02/28
17:47
02/28/21
17:47
MCD

McDonald's

$206.13 /

-2.27 (-1.09%)

McDonald's said it…

McDonald's said it is considering selling part of Dynamic Yield, its artificial intelligence startup that provides personalized digital promotions to consumers, Bloomberg's Crayton Harrison reports. "The potential sale of the non-McDonald's part of our business has been discussed from the outset and now feels like the right time to explore that possibility," Liad Agmon, founder and chief executive officer of Dynamic Yield, said. "We look forward to our continued relationship while continuing to expand the use of Dynamic Yield's technology at McDonald's restaurants around the world." Reference Link

ShowHide Related Items >><<
MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

02/22/21 Wells Fargo
Wells Fargo strategist upgrades Consumer Services sector to Overweight
02/01/21 Citi
Citi opens 'Catalyst Watch' on McDonald's into chicken sandwich launch
01/21/21 UBS
UBS sees 'golden' risk reward for McDonald's
01/19/21 Goldman Sachs
McDonald's initiated with a Buy at Goldman Sachs
MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

MCD McDonald's
$206.13 /

-2.27 (-1.09%)

Periodicals
Microsoft says vaccine tools have 'fallen short,' Bloomberg reports » 17:43
02/28/21
02/28
17:43
02/28/21
17:43
MSFT

Microsoft

$232.37 /

+3.21 (+1.40%)

Widely-used Microsoft…

Widely-used Microsoft vaccine scheduling software that has run into difficulties in states like Iowa and New Jersey is being blamed for problems that left some residents of the nation's capital unable to book appointments, Bloomberg's Ari Natter and Dina Bass report. After three straight days of issues with the District of Columbia's online vaccination registration, the company released a statement along with the city government acknowledging "that our efforts have fallen short" and vowing to address the problems, the authors note. "We understand the frustration of individuals who attempted to utilize the District's vaccination appointment portal this week," they said. "We are committed to address technical issues so that the vaccination appointment portal is properly functional and accessible." Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
02/08/21 RBC Capital
Datadog price target raised to $110 from $85 at RBC Capital
MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

MSFT Microsoft
$232.37 /

+3.21 (+1.40%)

Hot Stocks
CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ » 17:41
02/28/21
02/28
17:41
02/28/21
17:41
JNJ

Johnson & Johnson

$158.52 /

-4.28 (-2.63%)

Johnson & Johnson…

Johnson & Johnson announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization issued by the U.S. Food and Drug Administration. The ACIP recommendation will be forwarded to the Director of the CDC and the U.S. Department of Health and Human Services for review and adoption. The company's single-shot COVID-19 vaccine received EUA from the FDA on February 27, 2021. The terms of the EUA allow use of the vaccine while more data are gathered. The company plans to file for a Biologics License Application with the FDA later in 2021. Johnson & Johnson has begun shipping its COVID-19 vaccine and expects to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20M people in the U.S. The company plans to deliver 100M single-shot vaccines to the U.S. during the first half of 2021. The U.S. government will manage allocation and distribution of the vaccine in the U.S.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

JNJ Johnson & Johnson
$158.52 /

-4.28 (-2.63%)

Hot Stocks
BridgeBio, affiliate Origin Biosciences announce FDA approval of NULIBRY » 16:14
02/28/21
02/28
16:14
02/28/21
16:14
BBIO

BridgeBio

$70.63 /

+5.37 (+8.23%)

BridgeBio Pharma and…

BridgeBio Pharma and affiliate Origin Biosciences announced the U.S. Food and Drug Administration has approved NULIBRY for Injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A. This is the first therapy of its kind. The novel therapy was developed based on BridgeBio's commitment to developing a treatment for MoCD Type A in collaboration with the experts and families in the MoCD Type A community. MoCD Type A is an ultra-rare and progressive condition, known to impact less than 150 patients globally with a median survival of four years. MoCD Type A presents shortly after birth, often with severe encephalopathy and intractable seizures. NULIBRY is a first-in-class approved cPMP substrate replacement therapy. The efficacy of NULIBRY for the treatment of patients with MoCD Type A was established based on data from three clinical trials compared to data from a natural history study. In these studies, NULIBRY or recombinant cPMP reduced the risk of death by 82% compared to the untreated, genotype-matched, historical control group in the natural history study. At three years on study, the probability of survival in NULIBRY or rcPMP-treated patients was 84% compared to 55% for untreated genotype-matched patients in the historical control group at three years. In addition to the survival analysis, treatment with NULIBRY led to a reduction of urine concentrations of S-sulfocysteine, a toxic substance that leads to neurological damage, in patients with MoCD Type A, and the reduction was sustained with long-term treatment over 48 months. Animal studies have identified that NULIBRY has phototoxic potential. NULIBRY was reviewed under Priority Review and received Orphan Drug Designation, Breakthrough Therapy Designation and Rare Pediatric Disease Designation from the FDA. With this approval, the FDA also issued a Rare Pediatric Disease Priority Review Voucher to Origin.

ShowHide Related Items >><<
BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

02/22/21 JPMorgan
BridgeBio reinstated with an Overweight at JPMorgan
02/09/21
Fly Intel: Top five analyst initiations
02/09/21 Goldman Sachs
BridgeBio reinstated with a Buy at Goldman Sachs
01/11/21 H.C. Wainwright
BridgeBio price target raised to $87 from $64 at H.C. Wainwright
BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

  • 12
    Feb
  • 29
    May
BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

BBIO BridgeBio
$70.63 /

+5.37 (+8.23%)

Hot Stocks
Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 » 16:09
02/28/21
02/28
16:09
02/28/21
16:09
REGN

Regeneron

$450.48 /

-2.29 (-0.51%)

Regeneron Pharmaceuticals…

Regeneron Pharmaceuticals announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma. The trial met the primary endpoint of preventing early asthma reactions. The trial also met key secondary endpoints, including improved lung function and an increased amount of cat allergen that patients could tolerate following a single dose of treatment, from as early as the first assessment conducted at week 1. The results were shared in an oral presentation at the virtual 2021 American Academy of Allergy, Asthma and Immunology Annual Meeting. Cat allergy is primarily caused by exposure to Fel d 1, the major allergen in cat dander produced by all cats. Fel d 1 is spread to surrounding environments through airborne particles that adhere to clothing, carpets and furniture. Patients typically experience rapid onset of mild to severe symptoms including nasal congestion, itchy and watery eyes, chest tightening and wheezing. Currently, cat-induced allergic rhinitis is treated with antihistamines and intranasal corticosteroids with moderate efficacy. Allergen-specific immunotherapy takes 12-24 months to see clinical benefit and is contraindicated for patients with severe or uncontrolled asthma. Importantly, the association between cat allergy and asthma is significant, as more than 50% of cat-allergic patients have co-existing asthma. Although rare, cat allergy in these patients can potentially trigger life-threatening asthma attacks leading to hospitalization. REGN1908-1909 is a novel cocktail of two fully-human monoclonal IgG antibodies, designed to specifically bind and block the Fel d 1 allergen, thus preventing it from binding and triggering the endogenous antibodies that cause allergies. REGN1908-1909 was invented using Regeneron's proprietary VelocImmune technology. The Phase 2 randomized, double-blind proof-of-concept trial enrolled 56 cat-allergic patients with mild asthma who received a single dose of REGN1908-1909 600 mg or placebo delivered subcutaneously. This was followed by a 12-week assessment period during which patients underwent a 4-hour Cat Allergen Challenge at weeks 1, 4, 8 and 12 in an environmental exposure unit where they were exposed to cat allergen and monitored for allergic reactions. In order to establish a baseline, patients were also exposed to the EEU 1 week prior to receiving either REGN1908-1909 or placebo. Patients who took REGN1908-1909 experienced significant improvements during the Cat Allergen Challenge compared to those on placebo, which included: Reduced time to EAR for up to 3 months, improved ability to breathe, and improved cat allergen tolerance. Adverse events occurred in 76% of patients who received REGN1908-1909 and 78% of patients who received placebo. AEs more commonly observed with those receiving REGN1908-1909 included injection site reactions. The use of REGN1908-1909 to treat cat-allergic patients with mild asthma is investigational and its efficacy and safety have not been fully evaluated by any regulatory authority.

ShowHide Related Items >><<
REGN Regeneron
$450.48 /

-2.29 (-0.51%)

REGN Regeneron
$450.48 /

-2.29 (-0.51%)

02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
02/08/21 SVB Leerink
Regeneron price target raised to $640 from $623 at SVB Leerink
02/08/21 Credit Suisse
Regeneron price target lowered to $753 from $758 at Credit Suisse
REGN Regeneron
$450.48 /

-2.29 (-0.51%)

  • 27
    May
REGN Regeneron
$450.48 /

-2.29 (-0.51%)

REGN Regeneron
$450.48 /

-2.29 (-0.51%)

REGN Regeneron
$450.48 /

-2.29 (-0.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.